126 related articles for article (PubMed ID: 12778778)
1. Influence of tumor grade on expression of CA 125 in serum and tissue in patients with serous ovarian carcinoma.
But I
Wien Klin Wochenschr; 2003 Apr; 115(7-8):255-8. PubMed ID: 12778778
[TBL] [Abstract][Full Text] [Related]
2. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
3. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
4. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
Bakshi N; Rajwanshi A; Patel F; Ganguly NK
Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
[TBL] [Abstract][Full Text] [Related]
6. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
7. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
[TBL] [Abstract][Full Text] [Related]
8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
9. Combined prognostic importance of CA 125, histopathologic grade and DNA-index in advanced ovarian cancer.
Nyvang GB; Mogensen O; Bichel P; Jakobsen A
Eur J Gynaecol Oncol; 2000; 21(6):569-72. PubMed ID: 11214611
[TBL] [Abstract][Full Text] [Related]
10. IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma.
Malekzadeh M; Dehaghani AS; Ghaderi A; Doroudchi M
Cancer Biomark; 2013 Jan; 13(6):417-25. PubMed ID: 24595078
[TBL] [Abstract][Full Text] [Related]
11. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
[TBL] [Abstract][Full Text] [Related]
12. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
13. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
[TBL] [Abstract][Full Text] [Related]
14. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
16. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.
Schmidt M; Segev Y; Sadeh R; Suzan E; Feferkorn I; Kaldawy A; Kligun G; Lavie O
Int J Gynecol Cancer; 2018 Sep; 28(7):1311-1317. PubMed ID: 29958235
[TBL] [Abstract][Full Text] [Related]
17. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
18. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
20. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]